Home

Celldex Therapeutics, Inc. - Common Stock (CLDX)

15.94
-1.21 (-7.06%)
NASDAQ · Last Trade: Apr 6th, 2:32 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
7 Analysts Have This To Say About Celldex Therapeuticsbenzinga.com
Via Benzinga · March 20, 2025
This Microsoft Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursdaybenzinga.com
Via Benzinga · March 20, 2025
Forecasting The Future: 6 Analyst Projections For Celldex Therapeuticsbenzinga.com
Via Benzinga · February 28, 2025
Baidu, Informatica And Other Big Stocks Moving Lower In Tuesday's Pre-Market Sessionbenzinga.com
Via Benzinga · February 18, 2025
Demystifying Celldex Therapeutics: Insights From 6 Analyst Reviewsbenzinga.com
Via Benzinga · January 29, 2025
What Analysts Are Saying About Celldex Therapeutics Stockbenzinga.com
Via Benzinga · December 20, 2024
Beyond The Numbers: 11 Analysts Discuss Celldex Therapeutics Stockbenzinga.com
Via Benzinga · November 20, 2024
Analyst Expectations For Celldex Therapeutics's Futurebenzinga.com
Via Benzinga · October 28, 2024
Jasper Therapeutics Skin Disorder Candidate Data Fails To Cheer Investorsbenzinga.com
Jasper Therapeutics reports strong briquilimab efficacy in CSU with UAS7 reductions, dose-dependent responses, and Phase 2b plans by late 2025.
Via Benzinga · January 8, 2025
This HP Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Fridaybenzinga.com
Via Benzinga · September 27, 2024
A Closer Look at 10 Analyst Recommendations For Celldex Therapeuticsbenzinga.com
Via Benzinga · September 25, 2024
The Analyst Verdict: Celldex Therapeutics In The Eyes Of 7 Expertsbenzinga.com
Via Benzinga · September 9, 2024
7 Analysts Have This To Say About Celldex Therapeuticsbenzinga.com
Via Benzinga · August 12, 2024
CLDX Stock Earnings: Celldex Therapeutics Beats EPS, Beats Revenue for Q2 2024investorplace.com
CLDX stock results show that Celldex Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via InvestorPlace · August 9, 2024
Analyst Expectations For Celldex Therapeutics's Futurebenzinga.com
Via Benzinga · July 16, 2024
Analyst Expectations For Celldex Therapeutics's Futurebenzinga.com
Via Benzinga · June 3, 2024
Unveiling 4 Analyst Insights On Celldex Therapeuticsbenzinga.com
Via Benzinga · May 7, 2024
Why Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Sessionbenzinga.com
Via Benzinga · July 30, 2024
Lattice Semiconductor Posts Weak Q2 Results, Joins Symbotic, Woodward And Other Big Stocks Moving Lower In Tuesday's Pre-Market Sessionbenzinga.com
Via Benzinga · July 30, 2024
Why F5 Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · July 30, 2024
ViaSat & AST SpaceMobile Are Among Top 6 Mid Cap Stocks That Shined The Brightest Last Week (July 21-July 27): Are The Others In Your Portfolio?benzinga.com
Top mid-cap stocks of the week: ASTS up 47.88%, GSHD up 39.86%, VSAT up 30.78%, VKTX up 29.86%, BEAM up 23.93%, CLDX up 19.72%
Via Benzinga · July 28, 2024
CLDX Stock Earnings: Celldex Therapeutics Beats EPS, Misses Revenue for Q1 2024investorplace.com
CLDX stock results show that Celldex Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via InvestorPlace · May 6, 2024
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Fridaycooper-com
U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday.
Via Benzinga · March 1, 2024
Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Sessionbenzinga.com
Shares of Freshpet, Inc. (NASDAQ: FRPT) gained 15.5% to $106.29 after the company reported better-than-expected fourth-quarter financial results.
Via Benzinga · February 26, 2024
Celldex Stock Hits 11-Month High, Up 19%, On A Promising New Hives Treatmentinvestors.com
The company tested its treatment in chronic spontaneous urticaria. Almost 38% of patients had "complete control" after 12 weeks.
Via Investor's Business Daily · February 26, 2024